S100A9 and neoplasm: Indeed, the modifications induced by the doxorubicin/GTN combination on the tumor microenvironment and on the PMN-MDSCs (FATP2, CXCR2, NOS2, S100A9) are in favor of reprogramming these cells towards a less immunosuppressive PMN type phenotype [31].